DK2836491T3 - SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR - Google Patents

SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR Download PDF

Info

Publication number
DK2836491T3
DK2836491T3 DK13774979.2T DK13774979T DK2836491T3 DK 2836491 T3 DK2836491 T3 DK 2836491T3 DK 13774979 T DK13774979 T DK 13774979T DK 2836491 T3 DK2836491 T3 DK 2836491T3
Authority
DK
Denmark
Prior art keywords
degrees
polymorph
cancer
compound
theta
Prior art date
Application number
DK13774979.2T
Other languages
Danish (da)
English (en)
Inventor
Kevin Wayne Kuntz
Kuan-Chun Huang
Hyeong Wook Choi
Kristen Sanders
Steven Mathieu
Arani Chanda
Frank Fang
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Application granted granted Critical
Publication of DK2836491T3 publication Critical patent/DK2836491T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK13774979.2T 2012-04-13 2013-04-11 SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR DK2836491T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Publications (1)

Publication Number Publication Date
DK2836491T3 true DK2836491T3 (en) 2017-03-06

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19180479.8T DK3628670T3 (da) 2012-04-13 2013-04-11 Saltform til ezh2-hæmning
DK13774979.2T DK2836491T3 (en) 2012-04-13 2013-04-11 SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR
DK16191716.6T DK3184523T3 (da) 2012-04-13 2013-04-11 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19180479.8T DK3628670T3 (da) 2012-04-13 2013-04-11 Saltform til ezh2-hæmning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16191716.6T DK3184523T3 (da) 2012-04-13 2013-04-11 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.

Country Status (26)

Country Link
US (7) US9394283B2 (enExample)
EP (4) EP3184523B1 (enExample)
JP (3) JP6255382B2 (enExample)
KR (4) KR20250005505A (enExample)
CN (2) CN108358899B (enExample)
AU (2) AU2013245878B2 (enExample)
BR (1) BR112014025508B1 (enExample)
CA (1) CA2870005C (enExample)
CY (2) CY1119383T1 (enExample)
DK (3) DK3628670T3 (enExample)
ES (3) ES2617379T3 (enExample)
HR (2) HRP20170295T1 (enExample)
HU (3) HUE060881T2 (enExample)
IL (4) IL282732B2 (enExample)
IN (1) IN2014DN09068A (enExample)
LT (2) LT2836491T (enExample)
MX (2) MX384641B (enExample)
NZ (1) NZ700761A (enExample)
PL (3) PL3628670T3 (enExample)
PT (3) PT3628670T (enExample)
RS (2) RS59392B1 (enExample)
RU (1) RU2658911C2 (enExample)
SG (3) SG11201406468YA (enExample)
SI (2) SI3184523T1 (enExample)
SM (2) SMT201900501T1 (enExample)
WO (1) WO2013155317A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN104768555B (zh) 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
PL3628670T3 (pl) 2012-04-13 2023-02-20 Epizyme, Inc. Postać soli dla inhibicji ezh2
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
SG10201705989YA (en) * 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
MX376008B (es) * 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HK1214815A1 (zh) 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CN105473580A (zh) 2013-07-10 2016-04-06 葛兰素史密斯克莱知识产权（第2号）有限公司 Zeste同源物增强子2抑制剂
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
SI3057962T1 (sl) 2013-10-16 2024-01-31 Epizyme, Inc. Oblika hidrokloridne soli za ezh2 inhibicijo
AU2014337121A1 (en) * 2013-10-18 2016-04-14 Epizyme, Inc. Method of treating cancer
WO2015077193A1 (en) * 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
KR20220165809A (ko) 2013-12-06 2022-12-15 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
CA3162315A1 (en) 2019-12-20 2021-06-24 Marinus Jacobus Verwijs Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6060099A (en) 1998-09-30 2000-04-17 Procter & Gamble Company, The 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
ATE438624T1 (de) 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
PT1477186E (pt) 2002-02-19 2010-02-11 Shionogi & Co Antipruriginosos
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1891434B1 (en) 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CN103382176A (zh) 2005-10-19 2013-11-06 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
JP4931930B2 (ja) 2005-10-21 2012-05-16 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
ATE547514T1 (de) 2005-10-28 2012-03-15 Univ North Carolina Protein-demethylasen mit einer jmjc-domäne
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP1974055A4 (en) 2006-01-20 2010-01-27 Univ North Carolina DIAGNOSTIC AND THERAPEUTIC OBJECTIVES AGAINST LEUKEMIA
US20100016379A1 (en) 2006-05-15 2010-01-21 Irm Llc Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
JP2010505958A (ja) 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ 神経防護作用組成物および方法
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
CA2730064A1 (en) 2008-08-08 2010-02-11 Asim Kumar Debnath Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
EP2566327B1 (en) 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
PL2614369T3 (pl) 2010-09-10 2016-08-31 Epizyme Inc Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2607064T3 (es) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
EP2825161B1 (en) 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
PL3628670T3 (pl) 2012-04-13 2023-02-20 Epizyme, Inc. Postać soli dla inhibicji ezh2
CN104768555B (zh) 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
MX376008B (es) 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
SI3057962T1 (sl) 2013-10-16 2024-01-31 Epizyme, Inc. Oblika hidrokloridne soli za ezh2 inhibicijo

Also Published As

Publication number Publication date
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
EP3184523B1 (en) 2019-06-19
MX362339B (es) 2019-01-11
IN2014DN09068A (enExample) 2015-05-22
JP2015512942A (ja) 2015-04-30
AU2013245878B2 (en) 2017-10-12
NZ700761A (en) 2016-09-30
SI3184523T1 (sl) 2020-04-30
ES2931316T3 (es) 2022-12-28
ES2745016T3 (es) 2020-02-27
PL3184523T3 (pl) 2019-12-31
AU2018200168A1 (en) 2018-02-01
IL266165B (en) 2021-06-30
ES2617379T3 (es) 2017-06-16
EP3628670A1 (en) 2020-04-01
MX2014012380A (es) 2015-07-23
PL2836491T3 (pl) 2017-08-31
EP2836491A1 (en) 2015-02-18
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
LT3184523T (lt) 2020-02-10
SMT201700132T1 (it) 2017-05-08
AU2013245878A1 (en) 2014-10-30
SMT201900501T1 (it) 2019-11-13
CA2870005C (en) 2021-06-22
CY1119383T1 (el) 2018-02-14
US20230140327A1 (en) 2023-05-04
KR20250005505A (ko) 2025-01-09
EP3628670B1 (en) 2022-10-12
EP4190777A1 (en) 2023-06-07
KR20220123339A (ko) 2022-09-06
US12251386B2 (en) 2025-03-18
KR102438340B1 (ko) 2022-08-30
EP2836491A4 (en) 2015-09-16
EP3184523A1 (en) 2017-06-28
CN108358899B (zh) 2021-07-27
JP6255382B2 (ja) 2017-12-27
US9872862B2 (en) 2018-01-23
AU2018200168B2 (en) 2019-08-29
CY1122883T1 (el) 2022-03-24
HUE031976T2 (en) 2017-08-28
IL235045A0 (en) 2014-12-31
US20180243316A1 (en) 2018-08-30
KR20200066380A (ko) 2020-06-09
CN104603130B (zh) 2018-04-27
IL282732B2 (en) 2023-04-01
US20210137936A1 (en) 2021-05-13
JP2018002742A (ja) 2018-01-11
CN108358899A (zh) 2018-08-03
SG11201406468YA (en) 2015-01-29
PT3184523T (pt) 2019-09-26
US10821113B2 (en) 2020-11-03
SG10201608577RA (en) 2016-12-29
IL282732A (en) 2021-06-30
IL282732B (en) 2022-12-01
PT2836491T (pt) 2017-02-08
LT2836491T (lt) 2017-03-27
US10245269B2 (en) 2019-04-02
IL296199B1 (en) 2024-08-01
HUE045353T2 (hu) 2019-12-30
RS55690B1 (sr) 2017-07-31
MX384641B (es) 2025-03-14
KR20150002730A (ko) 2015-01-07
JP6634058B2 (ja) 2020-01-22
EP2836491B1 (en) 2016-12-07
SI2836491T1 (sl) 2017-06-30
JP2018199740A (ja) 2018-12-20
US20150065503A1 (en) 2015-03-05
DK3628670T3 (da) 2022-12-05
HRP20191653T1 (hr) 2020-02-21
RU2658911C2 (ru) 2018-06-26
IL296199B2 (en) 2024-12-01
KR102120883B1 (ko) 2020-06-09
PT3628670T (pt) 2022-12-02
PL3628670T3 (pl) 2023-02-20
HRP20170295T1 (hr) 2017-04-21
KR102744039B1 (ko) 2024-12-17
CN104603130A (zh) 2015-05-06
US20190269692A1 (en) 2019-09-05
IL296199A (en) 2022-11-01
US11491163B2 (en) 2022-11-08
WO2013155317A1 (en) 2013-10-17
DK3184523T3 (da) 2019-08-19
US20250268905A1 (en) 2025-08-28
SG10201912109QA (en) 2020-02-27
HUE060881T2 (hu) 2023-04-28
IL235045B (en) 2019-05-30
IL266165A (en) 2019-06-30
RU2014145544A (ru) 2016-06-10
US20170143729A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US12251386B2 (en) Salt form of a human histone methyltransferase EZH2 inhibitor
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition